Jennifer A Frontera1,2, J Javier Provencio3, Fatima A Sehba4, Thomas M McIntyre5, Amy S Nowacki6, Errol Gordon7, Jonathan M Weimer8, Louis Aledort9. 1. Cerebrovascular Center of the Neurological Institute, Cleveland Clinic, 9500 Euclid Ave. S80, Cleveland, OH, 44195, USA. frontej@ccf.org. 2. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. frontej@ccf.org. 3. Department of Neurology and Neuroscience, Brain Immunology and Glia Center, University of Virginia, Charlottesville, VA, USA. 4. Department of Neurosurgery, Mount Sinai School of Medicine, New York, NY, USA. 5. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. 6. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 7. Department of Critical Care, Mount Sinai School of Medicine, New York, NY, USA. 8. Cerebrovascular Center of the Neurological Institute, Cleveland Clinic, 9500 Euclid Ave. S80, Cleveland, OH, 44195, USA. 9. Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Abstract
BACKGROUND: Early brain injury (EBI) following aneurysmal subarachnoid hemorrhage (SAH) is an important predictor of poor functional outcome, yet the underlying mechanism is not well understood. Animal studies suggest that platelet activation and inflammation with subsequent microthrombosis and ischemia may be a mechanism of EBI. METHODS: A prospective, hypothesis-driven study of spontaneous, SAH patients and controls was conducted. Platelet activation [thromboelastography maximum amplitude (MA)] and inflammation [C-reactive protein (CRP)] were measured serially over time during the first 72 h following SAH onset. Platelet activation and inflammatory markers were compared between controls and SAH patients with mild [Hunt-Hess (HH) 1-3] versus severe (HH 4-5) EBI. The association of these biomarkers with 3-month functional outcomes was evaluated. RESULTS: We enrolled 127 patients (106 SAH; 21 controls). Platelet activation and CRP increased incrementally with worse EBI/HH grade, and both increased over 72 h (all P < 0.01). Both were higher in severe versus mild EBI (MA 68.9 vs. 64.8 mm, P = 0.001; CRP 12.5 vs. 1.5 mg/L, P = 0.003) and compared to controls (both P < 0.003). Patients with delayed cerebral ischemia (DCI) had more platelet activation (66.6 vs. 64.9 in those without DCI, P = 0.02) within 72 h of ictus. At 3 months, death or severe disability was more likely with higher levels of platelet activation (mRS4-6 OR 1.18, 95 % CI 1.05-1.32, P = 0.007) and CRP (mRS4-6 OR 1.02, 95 % CI 1.00-1.03, P = 0.041). CONCLUSIONS: Platelet activation and inflammation occur acutely after SAH and are associated with worse EBI, DCI and poor 3-month functional outcomes. These markers may provide insight into the mechanism of EBI following SAH.
BACKGROUND: Early brain injury (EBI) following aneurysmal subarachnoid hemorrhage (SAH) is an important predictor of poor functional outcome, yet the underlying mechanism is not well understood. Animal studies suggest that platelet activation and inflammation with subsequent microthrombosis and ischemia may be a mechanism of EBI. METHODS: A prospective, hypothesis-driven study of spontaneous, SAHpatients and controls was conducted. Platelet activation [thromboelastography maximum amplitude (MA)] and inflammation [C-reactive protein (CRP)] were measured serially over time during the first 72 h following SAH onset. Platelet activation and inflammatory markers were compared between controls and SAHpatients with mild [Hunt-Hess (HH) 1-3] versus severe (HH 4-5) EBI. The association of these biomarkers with 3-month functional outcomes was evaluated. RESULTS: We enrolled 127 patients (106 SAH; 21 controls). Platelet activation and CRP increased incrementally with worse EBI/HH grade, and both increased over 72 h (all P < 0.01). Both were higher in severe versus mild EBI (MA 68.9 vs. 64.8 mm, P = 0.001; CRP 12.5 vs. 1.5 mg/L, P = 0.003) and compared to controls (both P < 0.003). Patients with delayed cerebral ischemia (DCI) had more platelet activation (66.6 vs. 64.9 in those without DCI, P = 0.02) within 72 h of ictus. At 3 months, death or severe disability was more likely with higher levels of platelet activation (mRS4-6 OR 1.18, 95 % CI 1.05-1.32, P = 0.007) and CRP (mRS4-6 OR 1.02, 95 % CI 1.00-1.03, P = 0.041). CONCLUSIONS: Platelet activation and inflammation occur acutely after SAH and are associated with worse EBI, DCI and poor 3-month functional outcomes. These markers may provide insight into the mechanism of EBI following SAH.
Entities:
Keywords:
Early brain injury; Inflammation; Microthrombosis; Platelet; SAH; Subarachnoid hemorrhage
Authors: Jared M Pisapia; Xiangsheng Xu; Jane Kelly; Jamie Yeung; Geneive Carrion; Huaiyu Tong; Sudha Meghan; Omar M El-Falaky; M Sean Grady; Douglas H Smith; Sergei Zaitsev; Vladimir R Muzykantov; Michael F Stiefel; Sherman C Stein Journal: Exp Neurol Date: 2011-11-04 Impact factor: 5.330
Authors: Katja E Wartenberg; J Michael Schmidt; Jan Claassen; Richard E Temes; Jennifer A Frontera; Noeleen Ostapkovich; Augusto Parra; E Sander Connolly; Stephan A Mayer Journal: Crit Care Med Date: 2006-03 Impact factor: 7.598
Authors: Bappaditya Ray; Vijay M Pandav; Eleanor A Mathews; David M Thompson; Lance Ford; Lori K Yearout; Bradley N Bohnstedt; Shuchi Chaudhary; George L Dale; Calin I Prodan Journal: Transl Stroke Res Date: 2017-12-09 Impact factor: 6.829